Method for manufacturing of vardenafil and its salts
AssigneeZaklady Farmaceutyczne Polpharma S.A.
InventorsRoman Szramka, Jerzy Drygas, Marcin Szulc, Robert Rynkiewicz
Life of this patent
Estimating the term…
Loading patent…
AssigneeZaklady Farmaceutyczne Polpharma S.A.
InventorsRoman Szramka, Jerzy Drygas, Marcin Szulc, Robert Rynkiewicz
Estimating the term…
The method of synthesizing vardenafil base, in anhydrous conditions, by chlorosulfonation of 2-(2-etoxy-phenyl)-5 -methyl-7-propyl-iH-imidazo[5,1-fJ[1,2,4]triazin-4-one in a mixture of thionyl chloride and sulfurochloridic acid followed by amidation of the product, 4-etoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)benzene-sulfonic acid chloride with N-ethylpiperazine, in an aprotic solvent, in the presence of an inorganic base and the method of conversion the product, vardenafil base, to yield vardenafil monohydrochloride trihydrate having a melting point of 234° C. by contacting with water of the anhydrous modification V of vardenafil monohydrochloride in an organic solvent. The subject of the invention is also the anhydrous modification V of vardenafil monohydrochloride and its use in the preparation of vardenafil monohydrochloride trihydrate having a melting point of 234° C.
A method for manufacturing vardenafil and/or its salts, comprising chlorosulfonating 2-(2-ethoxy-phenyl)-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one in thionyl chloride mixed with sulfurochloridic acid under reflux at the solvent boiling point, isolating the synthesized 4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)benzene-sulfonic acid chloride from the reaction mixture under anhydrous conditions, amidating the 4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1-f][1,2,4]triazin-2-yl)benzene-sulfonic acid chloride with N-ethylpiperazine in an aprotic solvent in the presence of an inorganic base, and after completion of the reaction, isolating the prepared vardenafil base and optionally transforming the vardenafil base into a salt.
A method for manufacturing vardenafil monohydrochloride trihydrate having a melting point of 234° C. comprising:
An anhydrous modification V of vardenafil monohydrochloride in crystalline form characterized on powder diffractogram by the following set of peak positions, described by interplanar distances d (Å) and diffraction angles 2Θ(°):
Dependencies are inferred from the claim text.